Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

被引:50
作者
Chun, JH [1 ]
Kim, HK [1 ]
Lee, JS [1 ]
Choi, JY [1 ]
Hwangbo, B [1 ]
Lee, HG [1 ]
Park, SR [1 ]
Choi, IJ [1 ]
Kim, CG [1 ]
Ryu, KW [1 ]
Kim, YW [1 ]
Lee, JS [1 ]
Bae, JM [1 ]
机构
[1] Natl Canc Ctr, Res Inst Hosp, Gastr Canc Branch, Goyang 411769, Gyeonggi, South Korea
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2005年 / 28卷 / 02期
关键词
capecitabine; chemotherapy; docetaxel; pneumonitis; stomach cancer;
D O I
10.1097/01.coc.0000143877.53314.9c
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Docetaxel (T) and capecitabine (X) are active agents against gastric cancer with synergistic antitumor effects. We conducted the current phase II study to assess the response rate and toxicity of combination TX regimen in patients with metastatic gastric cancer. Eligible patients were treated with docetaxel (36 mg/m(2) intravenously) on days 1 and 8 and capecitabine (1000 mg/m(2) orally twice a day) on days 1-14 of a 3-week schedule until progression occurred. From December 2001 to May 2003, 55 patients with median age of 54 years (range, 22-73 years) were enrolled; 47 patients had measurable lesions. A total of 3 5 8 courses of treatment were given, with a median of 5 (range, 1-22+) per patient. Objective responses were documented in 19 of 47 patients with measurable lesions (response rate, 40.4%; 95% confidence interval [CI], 25.9-54.9), with the median response duration of 5.6 months (range, 2.1-13.6+). At a median follow up of 15.9 months for all of 55 study patients, the median time to progression and survival were 4.5 months (95% CI, 3.4-5.6) and 12.0 months (95% CI, 7.5-16.6), respectively. Hematologic toxicities were mild to moderate, and the observed grade 3 nonhematologic toxicities, the most frequent of which was stomatitis, were generally manageable. Four patients experienced pneumonitis, but all of them responded to steroid treatment. The TX regimen was relatively well tolerated and effective against metastatic gastric cancer, with the added advantage of being an outpatient regimen.
引用
收藏
页码:188 / 194
页数:7
相关论文
共 46 条
  • [1] Ajani JA, 2002, ONCOLOGY-NY, V16, P16
  • [2] CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma - Results of a Phase II study
    Ajani, JA
    Baker, J
    Pisters, PWT
    Ho, L
    Mansfield, PF
    Feig, BW
    Charnsangavej, C
    [J]. CANCER, 2002, 94 (03) : 641 - 646
  • [3] AJANI JA, 2003, P AN M AM SOC CLIN, V22, P249
  • [4] [Anonymous], P AM SOC ONCOL
  • [5] Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
    Boku, N
    Ohtsu, A
    Shimada, Y
    Shirao, K
    Seki, S
    Saito, H
    Sakata, Y
    Hyodo, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 319 - 323
  • [6] BOUCHE O, 2003, P AN M AM SOC CLIN, V22, P258
  • [7] BRUCKNER HW, 2000, CANC MED, V2, P1355
  • [8] Docetaxel administered on a weekly basis for metastatic breast cancer
    Burstein, HJ
    Manola, J
    Younger, J
    Parker, LM
    Bunnell, CA
    Scheib, R
    Matulonis, UA
    Garber, JE
    Clarke, KD
    Shulman, LN
    Winer, EP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) : 1212 - 1219
  • [9] Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases
    Chen, GY
    Chang, TW
    Chen, WC
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (05) : 1071 - 1073
  • [10] Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293
    Einzig, AI
    Neuberg, D
    Remick, SC
    Karp, DD
    ODwyer, PJ
    Stewart, JA
    Benson, AB
    [J]. MEDICAL ONCOLOGY, 1996, 13 (02): : 87 - 93